Genetic Signatures Ltd. · ASX:GSS
Genetic Signatures — Shareholder Meeting (November 2023)
20 slides from Genetic Signatures's shareholder meeting presentation, Nov 29, 2023
Slide 1: Chairman's Address and CEO Presentation
ASX Code: GSS 29 November 2023 Chairman’s Address and CEO Presentation at Annual General Meeting Genetic Signatures Limited (ASX:GSS) is pleased to release the Annual General Meeting Chairman’s Address and CEO presentation. Chairman’s Address: Good morning, and welcome to the Genetic Signatures 2023
Slide 2: Chairman's Address (continued)
This year, we continued to deliver high-impact marketing initiatives to further increase awareness and positioning of Genetic Signatures as a leading competitor in global molecular diagnostics in the lucrative United States (US) and European markets. In the US, Genetic Signatures remains focused on
Slide 3: 2023 Annual General Meeting
2023 Annual General Meeting 29 November 2023 1
Slide 4: Disclaimer
2023 Annual General Meeting Disclaimer 29 November 2023 2
Slide 5: 2023 Annual General Meeting
2023 Annual General Meeting 29 November 2023 • • • • • • 3
Slide 6: A revolutionary approach to molecular diagnostic assays for infectious diseases
2023 Annual General Meeting 29 November 2023 • A revolutionary approach to molecular diagnostic assays for infectious diseases • Detects a wide range of clinically relevant targets, in one test – Syndromic Testing - testing for multiple pathogens Proprietary 3base® technology that all can cause the
Slide 7: Next Generation Instrument development to drive future growth
2023 Annual General Meeting 29 November 2023 • Will enable customers to conduct automated, high-throughput syndromic testing improving efficiency, economics and patient diagnosis Next Generation Instrument development to drive future • Single platform which consolidates multiple tests that are curre
Slide 8: C→T most common mutation
2023 Annual General Meeting 29 November 2023 C→T most common mutation * Human Papilloma virus sequences 6
Slide 9: 2023 Annual General Meeting
2023 Annual General Meeting 29 November 2023 • • • • • • 7
Slide 10: Product pipeline and registration status
2023 Annual General Meeting 29 November 2023 DEVELOPMENT RESEARCH USE REGISTRATION TGA CE Mark FDA In clinical trials Submitted Converting to new protocol In development 8
Slide 11: Revenue $m
2023 Annual General Meeting 29 November 2023 • • • • 40 Pandemic 35 3.8 30 Revenue $m 25 6.0 20 15 31.6 1.6 22.2 10 1.1 15.4 10.2 5 4.9 0 FY2019 FY2020 FY2021 FY2022 FY2023 APAC Rest of world 9 NOTE: EasyScreen™ SARS-CoV-2 Detection Kit sales commenced during FY2020
Slide 12: Syndromic vs COVID-only revenue
2023 Annual General Meeting 29 November 2023 • • • • • Pandemic 40 35 30 25 26.4 20 16.4 15 4.3 10 1.7 5 11.8 12.6 9.6 9.1 4.9 0 FY2019 FY2020 FY2021 FY2022 FY2023 Syndromic COVID-only 10
Slide 13: New image
2023 Annual General Meeting 29 November 2023 New image • • • • • 11 11
Slide 14: US team representation at ASM Microbe 2023
2023 Annual General Meeting 29 November 2023 US team representation at ASM Microbe 2023 12 conference in Houston, Texas.
Slide 15: Target segments GI parasite testing
2023 Annual General Meeting 29 November 2023 *EP005 = EasyScreenTM Gastrointestinal Parasite Detection Kit Target GI parasite testing Potential TAM Share of targeted 2.2m Potential customers segments requirements = 5.5 m tests EP005* tests by segment • LabCorp High volume • Quest Large commercial 1.
Slide 16: Next generation instrument development stages
2023 Annual General Meeting 29 November 2023 • • • • • Images are concepts only • • • Design development • Performance testing • Research • Manufacturing • Sample to answer build • User feedback • FDA/IVDR submission • OEM review partnership • Consumable build • Informatics • Regulatory clearance •
Slide 17: 2023 Annual General Meeting
2023 Annual General Meeting 29 November 2023 • • • • • • • • • 15 15
Slide 18: Presentation by Professor Marc Couturier, PhD, ARUP Laboratories
2023 Annual General Meeting 29 November 2023 Presentation by Professor Marc Couturier, PhD ARUP Laboratories United States 16
Slide 19: Professor Marc Couturier, PhD
2023 Annual General Meeting Professor Marc Couturier, PhD 29 November 2023 Medical Director, Microbial Immunology, Parasitology and Fecal Testing, and Infectious Disease Rapid Testing, ARUP Laboratories Professor of Pathology at the University of Utah • • • • 17
Slide 20: Contact Us
Contact Us Dr John Melki Managing Director & Chief Executive Officer E: john.melki@geneticsignatures.com P: +61 (0)2 9870 7580 Karl Pechmann Chief Financial & Operating Officer & Company Secretary E: karl.pechmann@geneticsignatures.com Visit us www.geneticsignatures.com Follow us 18 18
Genetic Signatures — Shareholder Meeting (November 2023) on 6ix